Myasthenia Gravis PBMC
Powered by BiozAbout:Myasthenia Gravis PBMC samples are collected from clinically confirmed myasthenia gravis donors and cryopreserved in CryoStor CS10. Ideal for investigating autoreactive B and T cells, AChR and MuSK autoantibody production, regulatory T-cell function, and B-cell-directed therapeutics.
About Myasthenia Gravis PBMC
Myasthenia Gravis PBMC for Autoimmune Neuromuscular Junction Research
Human Myasthenia Gravis PBMC products are sourced from IRB-consented donors clinically diagnosed with myasthenia gravis (MG) and processed under stringent conditions within 24 hours of collection. MG is an antibody-mediated autoimmune disease of the neuromuscular junction, driven by IgG autoantibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). These cryopreserved peripheral blood mononuclear cells give direct access to the autoreactive B-cell and T-cell compartments that generate and sustain those antibodies.
Disease Biology and Why PBMC
- Autoreactive B cells and plasmablasts are the source of pathogenic AChR and MuSK autoantibodies; PBMCs allow their identification, sorting, and single-cell characterisation.
- Antigen-specific T-cell help: AChR-reactive CD4+ T cells and follicular helper T cells drive class-switched autoantibody production and can be profiled by tetramer, activation-induced marker, or cytokine assays.
- Regulatory T-cell function is impaired in MG and is a recognised research focus for tolerance-restoring therapy.
- MuSK-positive disease is IgG4-predominant, giving a distinct B-cell biology from complement-driven AChR-positive disease and a rationale for stratified cellular studies.
- B-cell-depleting and CAAR-T approaches: PBMCs support target engagement, repopulation, and cytotoxicity work for rituximab, anti-CD19/CD20, BAFF-directed, and chimeric autoantibody receptor T-cell programmes.
- Thymic biology: thymoma-associated and hyperplastic donors provide a peripheral window on a disease with a strong thymic component.
Donor Stratification Available
- Serostatus: AChR-positive, MuSK-positive, or seronegative
- Clinical subtype: ocular versus generalised MG
- Thymic pathology: thymoma-associated, thymic hyperplasia, or post-thymectomy
- Age at onset: early-onset versus late-onset disease
- Treatment status: corticosteroids, non-steroidal immunosuppressants, rituximab, complement inhibitors, FcRn antagonists, or treatment-naive
- Disease activity: stable, exacerbation, or history of myasthenic crisis
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed MG donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified MG diagnosis
- Serostatus (AChR, MuSK) where available
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional myasthenia gravis-specific data available upon request
Applications
- Autoreactive B-cell and plasmablast identification, sorting, and BCR repertoire sequencing
- Antigen-specific T-cell assays and T-cell receptor repertoire analysis
- Immunophenotyping by flow cytometry, spectral flow, or mass cytometry
- Regulatory T-cell frequency and suppression assays
- Single-cell RNA sequencing and bulk transcriptomic profiling
- B-cell depletion, FcRn antagonist, and CAAR-T target validation
- Ex vivo stimulation and cytokine release assays
- Biomarker discovery and drug screening in MG programmes
Other Myasthenia Gravis Specimen Types
MG donor material is also available as Myasthenia Gravis Plasma, Myasthenia Gravis Serum, Myasthenia Gravis Whole Blood, Myasthenia Gravis Leukopak, and Myasthenia Gravis Bulk Plasma.
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Myasthenia Gravis PBMC samples are shipped on dry ice and available in standard or custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. Browse all human PBMCs or request a custom disease-state collection.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), PBMC
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Myasthenia Gravis PBMC with normal donor samples for comparison
Healthy Donor PBMCs
705 In Stock View InventoryNeed a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.